Jefferies Says AstraZeneca Interest in Rhythm Pharmaceuticals Looks Sensible
Jefferies analysts say a potential acquisition would resemble AstraZeneca’s purchase of Alexion on a smaller scale. The Wall Street Journal reported that AstraZeneca made a roughly $10 billion offer for Rhythm Pharmaceuticals.